RE:ATRAAtara is a preclinical/Phase 1 allogeneic CAR-T cell company that develops allogeneic products on a EBV-T cell backbone. I have already posted that allogeneic CAR-T cell companies are having difficulty in batch-to-batch manufacturing reproducibility and that autologous CAR-T therapies will remain the standard treatment until such a time that that allogeneic CAR-T companies can demonstrate product reliability. So far these allogeneic companies have not been able to achieve this at a performance level suitable enough for the FDA.
Atara is trading at US$82.6 per share with a daily volume of approximately 55K shares traded per day.